Closed · RFA-FD-14-009 · CFDA 93.103 · Discretionary

Dissolution Methods for Suspension and Emulsion Ocular Drug Products

Federal grant opportunity posted by Food and Drug Administration, cataloged on Grants.gov.

$200K-$250K
Award range
Closed
Status
May 8, 2014
Close date
5
Expected awards

The verdict

Dissolution Methods for Suspension and Emulsion Ocular Drug Products is a closed discretionary listing from Food and Drug Administration that offered $200,000 -- $250,000 across 5 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 481 other opportunities from Food and Drug Administration.

$200K-$250K
award range
Closed
application status
5
expected awards
93.103
CFDA program

Archived opportunity record

Dissolution Methods for Suspension and Emulsi… is closed (last close May 8, 2014). The parent program page for CFDA 93.103 is the reliable place to catch re-announcements. Food and Drug Administration still indexes 481 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed May 8, 2014

Posted Mar 31 Closes May 8

Est. Total Funding

$500,000

Expected Awards

5

Instrument

Cooperative Agreement

Description

Dissolution testing is recommended as part of the demonstration of bioequivalence between test and reference products in the approval of most generic drugs. Drug release measurements are useful for evaluating the effect of manufacturing differences and to assess performance characteristics of a suspension or emulsion dosage form. Generally, a generic drug product intended for ocular use contains the same inactive ingredients (“Q1”) and in the same concentration (“Q2”) as the Reference Listed Drug (RLD). However, there may be differences in manufacturing of the generic and RLD products, which may affect bioavailability. Dissolution testing can be used as one of several standard methods to evaluate physicochemical differences of the drug product caused by manufacturing differences. The purpose of this study is to investigate dissolution methods for either an ocular suspension or emulsion drug product. The results from this study will help the FDA in developing recommendations to determine bioequivalence of generic ocular suspension and emulsion drug products.ObjectivesThe investigator should choose either an ocular suspension or emulsion dosage form for study. One award will be granted for each dosage form. Applicants are encouraged to apply to RFA-FD-14-008 “Dissolution Methods for Semisolid Ocular Drug Products” for investigating formulations which exhibit semisolid properties.The objectives of this project are:(1) To formulate Q1/Q2 topical ocular formulations (either as suspensions or emulsions) under different manufacturing conditions(2) To conduct dissolution studies with the prepared formulations using various in vitro release methods(3) To identify a dissolution method that can discriminate different formulations Detailed DescriptionAdditional details regarding the study objectives listed above:(1) The suspension or emulsion chosen to serve as the reference product for this study can either be a marketed product or an investigational formulation. Formulations which are Q1/Q2 to this reference product should be developed under different manufacturing conditions. Physicochemical characterization should be performed on these test formulations to determine key attributes that may affect bioavailability.(2) Before initiating the dissolution studies, an analysis of current dissolution methods used for suspension or emulsion products should be conducted. A report of this analysis should include the advantages and disadvantages for each method and an assessment on the capability of detecting manufacturing differences, predicting in vivo performance, and method robustness. Test formulations which have the largest differences in physicochemical properties (and which are expected to affect bioavailability) are chosen for testing in the dissolution study. Dissolution methods should be developed with considerations in drug substance and drug product properties and the physiological release environment.(3) An analysis of the dissolution methods used in the study should include the advantages and disadvantages for each method and an assessment on the capability of detecting manufacturing differences, predicting in vivo performance, and method robustness.4. # of awards: 2 (one award for a suspension, the other award for an emulsion)5. Due Date should be 30 days after the Open Date

Wide-open applicant board · 15 Grants.gov doors

Dissolution Methods for Suspension and Emulsi… prints 15 distinct Grants.gov eligibility doors (State governments; County governments; City or township governments; Special district governments; +11 more). Filter fit before reading award size as demand — most applicant classes appear on the row. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Health · Science and Technology / R&D (HL;ST). 120 other Food and Drug Administration listings share this eligibility-code string (25% of 482).

Code 00
State governments
Code 01
County governments
Code 02
City or township governments
Code 04
Special district governments
Code 05
Independent school districts
Code 06
Public / state-controlled institutions of higher education
Code 07
Federally recognized tribal governments
Code 08
Public / Indian housing authorities
Code 11
Native American tribal organizations (other than Federally recognized tribal governments)
Code 12
Nonprofits with 501(c)(3) status (other than IHEs)
Code 13
Nonprofits without 501(c)(3) status (other than IHEs)
Code 20
Private institutions of higher education
Code 22
For-profit organizations other than small businesses
Code 23
Small businesses
Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

Gladys Melendez-Bohler Grants Management Specialist Phone 301-827-7175

What to do next

Dissolution Methods for Suspension and Emulsi… is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.103 may publish future NOFOs under the same assistance listing. Open program
  • Food and Drug Administration Research indexes 42 Grants.gov listings in this extract. Program profile
  • Food and Drug Administration lists 481 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants